Interruption of recurrent Clostridium difficile -: Associated diarrhea episodes by serial therapy with vancomycin and rifaximin

被引：214

作者：

Johnson, Stuart

Schriever, Christopher

Galang, Minerva

Kelly, Ciaran P.

Gerding, Dale N.

机构：

[1] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA

[2] Loyola Univ, Med Ctr, Maywood, IL 60153 USA

[3] Beth Israel Deaconess Med Ctr, Boston, MA USA

[4] Harvard Univ, Boston, MA 02115 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2007年 / 44卷 / 06期

关键词：

D O I：

10.1086/511870

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Eight women who each experienced 4-8 episodes of Clostridium difficile-associated diarrhea were given a 2-week course of rifaximin therapy when they were asymptomatic, immediately after completing their last course of vancomycin therapy. Seven of the 8 patients experienced no further diarrhea recurrence. The patient who had a recurrence responded to a second course of rifaximin therapy, but rifaximin-resistant C. difficile was recovered after treatment. A controlled trial for treating recurrent Clostridium difficile associated diarrhea appears to be warranted.

引用

收藏

页码：846 / 848

页数：3

相关论文

共 12 条

[1]

[Anonymous], 2004, METH ANT SUSC TEST A

[2] Narrative review: The new epidemic of clostridium difficile-associated enteric disease [J].

Bartlett, John G. .

ANNALS OF INTERNAL MEDICINE, 2006, 145 (10) :758-764

[3] DEVELOPMENT OF A RAPID AND EFFICIENT RESTRICTION-ENDONUCLEASE ANALYSIS TYPING SYSTEM FOR CLOSTRIDIUM-DIFFICILE AND CORRELATION WITH OTHER TYPING SYSTEMS [J].

CLABOTS, CR ;

JOHNSON, S ;

BETTIN, KM ;

MATHIE, PA ;

MULLIGAN, ME ;

SCHABERG, DR ;

PETERSON, LR ;

GERDING, DN .

JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (07) :1870-1875

[4] A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea [J].

DuPont, HL ;

Jiang, ZD ;

Okhuysen, PC ;

Ericsson, CD ;

de la Cabada, FJ ;

Ke, S ;

DuPont, MW ;

Martinez-Sandoval, F .

ANNALS OF INTERNAL MEDICINE, 2005, 142 (10) :805-812

[5]

GERDING DN, 2005, AM SOC MICROBIOL, V79

[6] In vitro activity and fecal concentration of rifaximin after oral administration [J].

Jiang, ZD ;

Ke, S ;

Palazzini, E ;

Riopel, L ;

Dupont, H .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2205-2206

[7] In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species [J].

Marchese, A ;

Salerno, A ;

Pesce, A ;

Debbia, EA ;

Schito, GC .

CHEMOTHERAPY, 2000, 46 (04) :253-266

[8] Breaking the cycle:: Treatment strategies for 163 cases of recurrent Clostridium difficile disease [J].

McFarland, LV ;

Elmer, GW ;

Surawicz, CM .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (07) :1769-1775

[9] Alternative treatments for Clostridium difficile disease:: what really works? [J].

Mcfarland, LV .

JOURNAL OF MEDICAL MICROBIOLOGY, 2005, 54 (02) :101-111

[10] Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of Clostridium difficile-associated diarrhea [J].

O'Connor, D ;

Hynes, P ;

Cormican, M ;

Collins, E ;

Corbett-Feeney, G ;

Cassidy, M .

JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (08) :2846-2849